Sarepta Therapeutics, Inc. (0L35.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 2.17B |
| Enterprise Value | 2.41B |
| P/E Ratio | 185.33 |
| PEG Ratio | 0.37 |
| Price/Sales Ratio | 0.91 |
| Price/Book Ratio | 1.16 |
| Enterprise/Revenue | 1.21 |
| Enterprise/EBITDA | 15.26 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
Profitability
| Profit Margin | 0.01 |
| Operating Margin | -0.02 |
AD
Management Effectiveness
| Return On Assets | 0 |
| Return On Equity | 0.01 |
Income Statement
| Revenue | 2.2B |
| Revenue/Share | 18.47 |
| Gross Profit | 1.32B |
| EBITDA | -599.3M |
| Net Income | -713.41M |
| Diluted EPS | -7.13 |
Balance Sheet
| Total Cash | 878.78M |
| Total Cash/Share | 8.3 |
| Total Debt | 1.08B |
| Total Debt/Equity | 0.69 |
| Current Ratio | 3.46 |
| Book Value Per Share | 14.43 |
Price History
| 52-Week Change | -8.7 |
| 52-Week High | 24.5 |
| 52-Week Low | 14.7 |
| Moving Average 50 Days | 18.96 |
| Moving Average 200 Days | 18.59 |
Statistics
| Average Volume | 5,723 |
| Shares Outstanding | 104.92M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
